3-(4,5-dimethyl-1H-imidazol-2-yl)aniline | 937685-61-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(4,5-dimethyl-1H-imidazol-2-yl)aniline
• CAS: 937685-61-5
• 化学式: C₁₁H₁₃N₃
• 分子量: 187.24
• InChiKey: ZTSRKENYTCXROD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] AMIDE COMPOUNDS<br/>[FR] COMPOSES AMIDES
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2001025229A1

  公开（公告）日：2001-04-12

  Amide compounds of formula (I) wherein R1 is an N-containing heterocyclic group selected from imidazolyl, triazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, each of which may be substituted with one or more lower alkyl groups, R2 is a hydrogen atom or a lower alkyl group, and R3 is a phenyl group substituted with thienyl or halophenyl; a thienyl group substituted with thienyl, phenyl or halophenyl; a pyrrolyl group substituted with phenyl; a thiazolyl group substituted with phenyl; an indolyl group substituted with lower alkyl and/or halo(lower)alkyl; a fluorenyl group; or a carbazolyl group, and salts thereof which have 5-HT antagonism activity.

  化合物的式子为（I），其中R1是一种含氮杂环基团，可选自咪唑基，三唑基，吡啶基，吡嗪啉基，嘧啶基和吡嗪基，每个基团都可以用一个或多个较低烷基基团取代；R2是氢原子或较低烷基基团；R3是苯基，取代有噻吩基或卤代苯基；取代有噻吩基，苯基或卤代苯基的噻吩基；取代有苯基的吡咯基；取代有苯基的噻唑基；取代有较低烷基和/或卤代较低烷基的吲哚基；芴基；或咔唑基，以及具有5-HT拮抗活性的盐。
• AMIDE COMPOUNDS
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1216240A1

  公开（公告）日：2002-06-26
• [EN] N-CONTAINING HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSES HETEROCYCLIQUES CONTENANT DE L'AZOTE
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2001087845A2

  公开（公告）日：2001-11-22

  A compound of the formula (I): wherein A is a hydrogen atom, an optionally substituted, unsaturated, N-containing heterocyclic group or a group of the formula (a) : wherein R is an optionally substituted aryl group or an optionally substituted heterocyclic group;M is -(CH2)n-, -(CH2)n-O-(CH2)m- or -(CH2)n-NH-(CH2)m-, wherein n and m are independently 0,1 or 2; Q is an optionally substituted cycloalkylene group, an optionally substituted arylene group or an optionally substituted divalent heterocyclic group; andthe moiety of the formula (b): is an optionally substituted, unsaturated, mono-, di-, tri- or tetra-cyclic, N-containing heterocyclic group which may contain additional hetero atom(s) selected from the group consisting of nitrogen, oxygen and sulfur atoms as the ring member(s), its prodrug or a pharmaceutically acceptable salt thereof.